Schepens Eye Research Institute grants ReNeuron exclusive, worldwide rights to co-develop REN003 to treat retinal disorders

Schepens Eye Research Institute

U.S. / Non-Profit or Major Disease Foundation

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

ReNeuron Group plc

U.K. / Small-Cap Biopharma (<$1 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced